TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Age of Red Blood Cells in Premature Infants Study (ARIPI)
Brief Summary: To determine if the age of blood transfused to new borns in the NICU setting has an impact on their outcome.


Options:
A: Aim 1:

Inclusion Criteria:

* Healthy male or female volunteers (age 21-60 years)

Must meet guidelines for blood donors including:

* standard blood donor history questionnaire
* body weight of at least 110 lbs
* hemoglobin concentration of at least 12.5 gm/dL
* body temperature of no more than 99.5 oF
* pulse of 50-100 bpm
* blood pressure \< 180/100
* test negative for the standard battery of blood donor screening tests (anti-HIV, HIV RNA, anti-HCV, HCV RNA, HBsAg, anti-HBc, anti-HTLV-I/II, and WNV RNA)

Aim 1:

Exclusion Criteria:

* Failure to pass the blood donor history questionnaire
* Positive results on the standard battery of blood donor screening tests
* Failure to meet criteria for donation

Aim 2:

Inclusion Criteria:

* Healthy male or female volunteers (age 21-80 years)

Exclusion Criteria:

* Presence of intercurrent illness or other chronic diseases
* Renal failure (creatinine\>1.4 mg/dl)
* Pregnancy
* Allergies to aspirin
* Bleeding disorders
* Uncontrolled hypertension with BP \> 180 mmHg systolic and \> 120 mmHg diastolic
* Acute infection in previous 4 weeks
* History of substance abuse
* Liver failure (Liver enzymes \>2x normal)
* Inability to give informed consent
* Inability to return to Emory for follow-up
B: Inclusion Criteria:

* All primary and reoperative adult cardiac surgical patients undergoing cardiopulmonary bypass for coronary artery bypass grafting, coronary artery bypass grafting with a valve procedure, isolated valve procedures, ascending aortic aneurysm or dissection repair alone or combined with CABG and valve procedures

Exclusion Criteria:

* Age less than 18 years
* Descending thoracic aortic aneurysm repairs
* Left or right ventricular assist devices
* Those unable to receive blood for religious reasons
C: Inclusion Criteria:

* healthy
* male body weight \>130 lbs, female body weight \> 155 lbs
* male height \>5'1", female height \>5'5"
* hemoglobin \>13.3 g/dL

Exclusion Criteria:

* ineligible for donation based on the New York Blood Center autologous blood donor questionnaire
* systolic blood pressure \>180 or \<90 mm Hg
* diastolic blood pressure \>100 or \<50 mm Hg
* heart rate \<50 or \>100
* temperature \>99.5 F prior to donation
* temperature \>100.4 F or subjective feeling of illness prior to transfusion
* positive results on standard blood donor infectious disease testing
* pregnancy.
D: Inclusion Criteria:

* birthweight of less than 1250g
* admitted to participating NICU
* consent acquired from proxy for the patient

Exclusion Criteria:

* already received one or more transfusions
* requirement for an exchange transfusion
* will be receiving directed donations
* have rare blood types/difficult cross-match
* proxy has refused consent
* moribund on admission to NICU/expected to die
* mitigating child protection issues

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Age of Red Blood Cells in Premature Infants Study (ARIPI)
Brief Summary: To determine if the age of blood transfused to new borns in the NICU setting has an impact on their outcome.


Options:
A: Inclusion Criteria:

* Blunt trauma mechanism of brain injury
* Glasgow Coma Score - motor component ≤ 5 (not following commands) on the post-resuscitation neurologic exam
* Available for enrollment and administration of study drug within 6 hours of injury

Exclusion Criteria:

* Penetrating trauma (i.e. gun shot wounds)
* Glasgow Coma Score = 3 and bilateral fixed and dilated pupils
* Abbreviated Injury Scale score \> 5 for any body part except brain
* Severe pre-existing chronic disease
* Uncontrolled hypertension, defined as mean arterial pressure \> 130mmHg despite antihypertensive treatment
* Known hypersensitivity to mammalian cell-derived products or human albumin
* Currently taking anticoagulants
B: Inclusion Criteria:

* must have clinically significant symptoms of depression;
* must be current recipients of services at CBOCs associated with the Houston and Oklahoma City VAMCs.

Exclusion Criteria:

* cognitive impairment;
* presence of bipolar, psychotic or substance-abuse disorders.
* Veterans currently receiving psychotherapy WILL be excluded.
C: Inclusion Criteria:

* birthweight of less than 1250g
* admitted to participating NICU
* consent acquired from proxy for the patient

Exclusion Criteria:

* already received one or more transfusions
* requirement for an exchange transfusion
* will be receiving directed donations
* have rare blood types/difficult cross-match
* proxy has refused consent
* moribund on admission to NICU/expected to die
* mitigating child protection issues
D: Inclusion Criteria:

* Patients hospitalised in ICU with an anticipated ICU stay of at least 24 hours, in whom the decision has been made by medical staff to transfuse at least one RBC unit.

Exclusion Criteria:

* Age younger than 18
* Previous RBC transfusion during the current hospital admission (including transfusion in another hospital for transferred patients)
* Diagnosis of transplantation or hematologic diseases
* Pregnancy
* Cardiac surgery during the present hospital admission
* Expected to die imminently (\<24hrs)
* The treating physician believes it is not in the best interest of the patient to be randomised in this trial.
* Known objection to the administration of human blood products
* Participation in a competing study (see below)

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Age of Red Blood Cells in Premature Infants Study (ARIPI)
Brief Summary: To determine if the age of blood transfused to new borns in the NICU setting has an impact on their outcome.


Options:
A: Inclusion Criteria:

* birthweight of less than 1250g
* admitted to participating NICU
* consent acquired from proxy for the patient

Exclusion Criteria:

* already received one or more transfusions
* requirement for an exchange transfusion
* will be receiving directed donations
* have rare blood types/difficult cross-match
* proxy has refused consent
* moribund on admission to NICU/expected to die
* mitigating child protection issues
B: Inclusion Criteria:

* birth weight \<1000g
* postnatal age \<48 hours
* no transfusion beyond first 6 hours of life
* estimated gestational age of 30 completed weeks or less

Exclusion Criteria:

* infant considered non-viable by attending physician
* infant has cyanotic congenital heart disease
* infant's parents known to be opposed to blood transfusion
* either parent has hemoglobinopathies or congenital anemias
* infant has hemolytic disease
* infant has severe acute hemorrhage, severe shock, severe sepsis with coagulopathy or requires peri-operative transfusion
* prior treatment with or intention to treat with erythropoietin
C: Inclusion Criteria:

1. age \< 18 years
2. surgical repair at URMC by the pediatric cardiac surgical team
3. informed consent signed by the parent or legal guardian, and if applicable, assent obtained from the subject.

Exclusion Criteria:

1. Age ≥18 years
2. inability to provide consent/assent; 3) subjects having "emergent" surgical procedures. Subjects with chronic inflammatory or autoimmune disorders will not be excluded
D: Inclusion Criteria:

* Undergoing repair of ventricular septal defect within 9 months of study entry
* Tetralogy of fallot
* D-transposition of the great arteries
* Atrio-ventricular septal defect

Exclusion Criteria:

* Birth weight less than 2.3 kg
* Recognizable phenotypic syndrome of congenital anomalies
* Extracardiac anomalies of greater than minor severity
* Previous cardiac surgery
* Associated cardiovascular anomalies requiring aortic arch reconstruction or additional open surgical procedures before the planned developmental follow-up

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Efficacy of Tranexamic Acid on Perioperative Blood Loss During Hip Fracture Surgery.
Brief Summary: The purpose of this study is to assess the efficacy of tranexamic acid in hip fracture surgery on the reduction of allogeneic red blood cell transfusion.


Options:
A: Inclusion Criteria:

* Patient requiring surgery for an isolated hip fracture of less than 48 hours

Exclusion Criteria:

* Contraindication to tranexamic acid
* Contraindication to fondaparinux
* Contraindication to general anesthesia associated with a femoral nerve block
* pregnancy
B: Inclusion Criteria:

All trauma patients with ongoing significant haemorrhage (systolic blood pressure less than 90 mmHg and/or heart rate more than 110 beats per minute), or who are considered to be at risk of significant haemorrhage, and are within 8 hours of the injury, are eligible for trial entry if they appear to be at least 16 years old. Although entry is allowed up to 8 hours from injury, the earlier that patients can be treated the better.

Exclusion Criteria:

The fundamental eligibility criterion is the responsible doctor's 'uncertainty' as to whether or not to use an antifibrinolytic agent in a particular adult with traumatic haemorrhage. Patients for whom the responsible doctor considers there is a clear indication for antifibrinolytic therapy should not be randomised. Likewise, patients for whom there is considered to be a clear contraindication to antifibrinolytic therapy (such as, perhaps, those who have clinical evidence of a thrombotic disseminated intravascular coagulation) should not be randomised. Where the responsible doctor is substantially uncertain as to whether or not to use an antifibrinolytic, all these patients are eligible for randomisation and should be considered for the trial. There are no other pre-specified exclusion criteria
C: Inclusion Criteria:

* All adults (patients over the age of eighteen years) who were scheduled for a primary unilateral total hip arthroplasty due to osteoarthritis at Ziekenhuis Oost-Limburg, Genk, Belgium are eligible for inclusion in the study.

Exclusion Criteria:

* History of coagulopathy
* Allergy to tranexamic acid
* preoperative anemia
* fibrinolytic disorders
* history of arterial or venous thromboembolic disease
* disturbances of color vision
* pregnancy
* breastfeeding
* major comorbidities
* participation in another clinical trial
D: Inclusion Criteria:

* Intertrochanteric Hip Fracture
* Age \>18

Exclusion Criteria:

* Preoperative use of anticoagulant (Clopidogrel, Warfarin, Enoxaparin, Fondaparinux, Rivaroxaban
* Allergy to Tranexamic Acid
* History of intracranial hemorrhage or significant GI or retroperitoneal bleed requiring hospitalization
* History of thromboembolic event (Stroke, Deep Vein Thrombosis, Pulmonary Embolism)
* History of cirrhosis or evidence of hepatic (AST/ALT \>60) or renal dysfunction (Cr \>1.5 or GFR \<30)
* Coronary stents or prior diagnosis of CAD
* Color blindness

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Efficacy of Tranexamic Acid on Perioperative Blood Loss During Hip Fracture Surgery.
Brief Summary: The purpose of this study is to assess the efficacy of tranexamic acid in hip fracture surgery on the reduction of allogeneic red blood cell transfusion.


Options:
A: Inclusion Criteria:

* Patient requiring surgery for an isolated hip fracture of less than 48 hours

Exclusion Criteria:

* Contraindication to tranexamic acid
* Contraindication to fondaparinux
* Contraindication to general anesthesia associated with a femoral nerve block
* pregnancy
B: Inclusion Criteria:

* informed consent
* Patients undergoing primary CABG or Aortic valve replacement surgery

Exclusion Criteria:

* Previous sternotomy
* OPCAB surgery
* urgent/emergency operation
* Coumadin treatment
* previous aprotinin exposure
* preoperative renal impairment (Creatinine \> 2 mg/dL)
* patients refusing blood transfusions
* no informed consent
C: Inclusion Criteria:

* Diagnosis of spondylosis, pseudoarthrosis, kyphoscoliosis, or acquired or congenital spine deformity
* Willing to undergo elective spinal surgery by a participating surgeon; eligible procedures include the following: spine osteotomy, arthrodesis, instrumentation and/or corpectomy, surgery for lumbar spinal stenosis, or surgery for degenerative disc disease

Exclusion Criteria:

* Requires urgent or emergent surgery
* Has kidney failure that requires dialysis
* Has a known bleeding diathesis, defined as a documented history of an inherited bleeding disorder (e.g., hemophilia or von Willebrand's disease) OR prothrombin time ratio greater than 1.5 seconds OR a documented previous arterial or venous thrombosis within 1 year of study entry
* Pregnant
D: Inclusion Criteria:

All trauma patients with ongoing significant haemorrhage (systolic blood pressure less than 90 mmHg and/or heart rate more than 110 beats per minute), or who are considered to be at risk of significant haemorrhage, and are within 8 hours of the injury, are eligible for trial entry if they appear to be at least 16 years old. Although entry is allowed up to 8 hours from injury, the earlier that patients can be treated the better.

Exclusion Criteria:

The fundamental eligibility criterion is the responsible doctor's 'uncertainty' as to whether or not to use an antifibrinolytic agent in a particular adult with traumatic haemorrhage. Patients for whom the responsible doctor considers there is a clear indication for antifibrinolytic therapy should not be randomised. Likewise, patients for whom there is considered to be a clear contraindication to antifibrinolytic therapy (such as, perhaps, those who have clinical evidence of a thrombotic disseminated intravascular coagulation) should not be randomised. Where the responsible doctor is substantially uncertain as to whether or not to use an antifibrinolytic, all these patients are eligible for randomisation and should be considered for the trial. There are no other pre-specified exclusion criteria

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Efficacy of Tranexamic Acid on Perioperative Blood Loss During Hip Fracture Surgery.
Brief Summary: The purpose of this study is to assess the efficacy of tranexamic acid in hip fracture surgery on the reduction of allogeneic red blood cell transfusion.


Options:
A: Inclusion Criteria:

* All elective primary and redo adult cardiac surgical patients for coronary artery bypass grafting, valve procedure or combined procedures
* Adults patients
* Written informed consent

Exclusion Criteria:

* Age less than 18 years
* Transplant procedures
* Emergency procedures
* Aortic repairs
* Congenital procedures
* Previous anemia (hemoglobin lower than 10 g/dL)
* Previous thrombocytopenia (platelet number lower than 100.000/mm3)
* Previous known coagulopathy
* Pregnancy
* Those unable to receive blood transfusion
* Patients who refused participation in the study
B: Inclusion Criteria:

* Primary hip fracture
* capable of informed consent
* independently dwelling
* able to ambulate independent of human assistance
* no active heart condition defined as no AMI within 3 months, no unstable angina or present incompensation/pulmonary oedema
* no regular transfusion demand or terminal disease.

Exclusion Criteria:

* Multiple fractures
* postop. immobilization due to to surgical reasons
* patient refusal to participate in relevant rehabilitation
* reoperation within 4. postoperative day.
C: Inclusion Criteria:

* Patient requiring surgery for an isolated hip fracture of less than 48 hours

Exclusion Criteria:

* Contraindication to tranexamic acid
* Contraindication to fondaparinux
* Contraindication to general anesthesia associated with a femoral nerve block
* pregnancy
D: Inclusion Criteria:

* The patient remains in the ICU after 96 hours (4 days) or more following ICU admission
* The patient has required mechanical ventilation via an endotracheal tube or tracheostomy tube for 96 hours or more
* The patient is expected to require ≥24 hours of further mechanical ventilation at the time of assessment
* The patient is aged ≥55 years of age
* The patient has a Hb value of 90g/L or less at the time of assessment

Exclusion Criteria:

* Patient with active bleeding at the time of screening
* Patient with traumatic brain injury as presenting diagnosis
* Patient with intracranial haemorrhage as presenting diagnosis
* Patient not expected to survive the next 48 hours at the time of assessment.
* Patient objects to RBC transfusion
* Patient receiving concurrent treatment with erythropoietin or similar erythropoietic agent
* Follow up is not feasible
* Already enrolled in another RCT with similar clinical endpoints

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Efficacy of Tranexamic Acid on Perioperative Blood Loss During Hip Fracture Surgery.
Brief Summary: The purpose of this study is to assess the efficacy of tranexamic acid in hip fracture surgery on the reduction of allogeneic red blood cell transfusion.


Options:
A: Inclusion Criteria:

* Hospitalized patients with hemoglobin level less than 100 g/L who present with an ST-segment Elevation Myocardial Infarction (STEMI), or Non-ST-Elevation Myocardial Infarction (NSTEMI);
* Rise in cardiac biomarker values with at least one value above the 99th percentile (preferably cardiac troponin cTn )
* Presence of one of the following:

  * symptoms of ischemia;
  * new/presumed new ST segment-T wave (ST-T) changes or new left bundle branch (LBBB);
  * development of pathological Q waves;
  * imaging evidence of new loss of viable myocardium or new regional wall motion abnormality;
  * identification of an intracoronary thrombus by angiography

Exclusion Criteria:

* Patients with uncontrolled acute bleeding at the time of randomization defined as the need for uncrossed or non-type specific blood;
* Patients who decline blood transfusion;
* Patients who have a planned cardiac surgery or immediate post-cardiac surgery;Patients who have been deemed palliative by their treatment team (no commitment to aggressive on-going care);
* If known that follow-up will not be possible at 30 days;
* Previous participation in the MINT Trial.
B: Inclusion Criteria:

* All elective primary and redo adult cardiac surgical patients for coronary artery bypass grafting, valve procedure or combined procedures
* Adults patients
* Written informed consent

Exclusion Criteria:

* Age less than 18 years
* Transplant procedures
* Emergency procedures
* Aortic repairs
* Congenital procedures
* Previous anemia (hemoglobin lower than 10 g/dL)
* Previous thrombocytopenia (platelet number lower than 100.000/mm3)
* Previous known coagulopathy
* Pregnancy
* Those unable to receive blood transfusion
* Patients who refused participation in the study
C: Inclusion Criteria:

* Patient requiring surgery for an isolated hip fracture of less than 48 hours

Exclusion Criteria:

* Contraindication to tranexamic acid
* Contraindication to fondaparinux
* Contraindication to general anesthesia associated with a femoral nerve block
* pregnancy
D: Inclusion Criteria:

* Documented cancer
* Planned treatment with chemotherapy
* Age older than 18 years
* Informed consent

Exclusion Criteria:

* Heart failure (NYHA 3 and 4)
* Prior serious complications to blood transfusion
* Medical conditions that require special considerations for blood transfusion
* Treatment with erythropoiesis-stimulating agents

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Effect Of LDL-Cholesterol, Lowering Beyond Currently Recommended Minimum Targets On Coronary Heart Disesse (CHD) Recurrence In Patients With Pre-Existing CHD
Brief Summary: The primary objective of this study is to determine the degree of additional reduction in cardiovascular risk that was accrued to patients by lowering their LDL-C beyond the currently accepted minimum target level for patients with pre-existing CHD. Secondary objectives include the safety profile of this treatment strategy, its cost-effectiveness, effect on other atherosclerotic-related events and procedures, and total mortality.


Options:
A: Inclusion Criteria

* Dyslipidemic participants with Chronic Kidney Disease Stage 3
* For entry into the Treatment Phase (Visit 3), the participant satisfied the following laboratory criteria (measured at the Screening Visit\[s\]):

  * Estimated glomerular filtration rate between 30 and 59 mL/min/1.73 m2 (Chronic Kidney Disease Stage 3) by simplified 4 variable Modification of Diet in Renal Disease formula (this includes a 10 percent variation in the upper limit of estimated glomerular filtration rate that was allowed for the enrollment of participants to account for variability in the creatinine assay).
  * Fasting lipid results following greater than or equal to 12-hour fasting period:
* Triglycerides level greater than or equal to 150 mg/dL,
* High-density lipoprotein cholesterol less than 40 mg/dL for males and less than 50 mg/dL for females, and
* Low-density lipoprotein cholesterol greater than or equal to 130 mg/dL Exclusion Criteria
* Participants with certain chronic or unstable medical conditions.
* Participants with unstable dose of medications or receiving coumarin anticoagulants, systemic cyclosporine, or certain other medications.
* Pregnant or lactating women, or women intending to become pregnant.
* Participants with diabetes mellitus that is poorly controlled.
* Participants of Asian ancestry (having Filipino, Chinese, Japanese, Korean, Vietnamese, or Asian-Indian origin).
B: Inclusion Criteria:

* hyperlipidemia
* urinary protein
* diabetes

Exclusion Criteria:

* previous rosuvastatin treatment \< 6 months prior to Visit 1
* statin intolerance
* severe hypertension
C: Inclusion Criteria:

Men and women age 35-75 who have evident CHD

Exclusion Criteria:

Known hypersensitivity to HMG CO-A reductase therapy, liver disease, evidence of secondary hyperlipidemia
D: Inclusion Criteria:

* Men 50 years or older, women 60 years or older
* Low to normal levels of low density lipoprotein (LDL) cholesterol (\< 130mg/dL)
* Elevated levels of C-Reactive Protein (CRP) \> 2.0 mg/L

Exclusion Criteria:

* History of cardiovascular or cerebrovascular events
* Active liver disease
* Diabetes mellitus
* Uncontrolled hypertension or hypothyroidism
* History of certain malignancies
* Chronic inflammatory conditions
* History of alcohol or drug abuse

Answer: C